Close Menu

NEW YORK (GenomeWeb) – The China Food and Drug Administration has approved Amoy Diagnostics' SuperARMS EGFR mutation analysis test as a companion diagnostic for EGFR TKI-based non-small cell lung cancer drugs, the company said today.

According to Xiamen, China-based AmoyDx, the real-time PCR-based test is designed to identify EGFR mutations in circulating tumor DNA in plasma samples from patients with advanced or metastatic NSCLC. The test was CE-IVD marked in April.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Oct
23
Sponsored by
Swift Biosciences

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries. 

Oct
24
Sponsored by
Sunquest

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.

Oct
31
Sponsored by
PerkinElmer

This webinar will provide an overview of how the Center for Applied Genomics at Children's Hospital of Philadelphia has optimized its next-generation sequencing (NGS) workflow using a combination of PerkinElmer's Sciclone automation technology and target capture chemistry from Twist Bioscience.

Nov
04
Sponsored by
Roche

This webinar will provide a look at how the Institute of Hematopathology in Hamburg, Germany, is implementing complex genomic testing for lung cancer.